Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133648) titled 'A Single-Arm, Exploratory Clinical Study of Adebelimumab in Combination with the AG Regimen for the Treatment of Potentially Resectable Cholangiocarcinoma' on Sept. 30.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Shandong Provincial Hospital

Condition: Potentially Resectable Locally Advanced Malignant Bile Duct Tumors

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-09-30

Target Sample Size: Experimental Group:26;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=340053

Published by HT Digital ...